ChemoCentryx, Inc.
COMBINATION THERAPY USING C-C CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE IMMUNE CHECKPOINT INHIBITORS
Last updated:
Abstract:
The present disclosure is drawn to the combination therapy of a C--C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.
Status:
Application
Type:
Utility
Filling date:
28 Aug 2019
Issue date:
5 Mar 2020